TriSalus Life Sciences Inc. (TLSI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, TriSalus Life Sciences Inc. (TLSI) has a cash flow conversion efficiency ratio of 0.139x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.71 Million) by net assets ($-26.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TLSI defensive interval ratio to measure how many days the company can operate on defensive assets alone.
TriSalus Life Sciences Inc. - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how TriSalus Life Sciences Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
TriSalus Life Sciences Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TriSalus Life Sciences Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Seohee Construction Co. Ltd
KQ:035890
|
-0.100x |
|
Armac Locacao Logistica
SA:ARML3
|
0.068x |
|
CSG Holding Co Ltd
SHE:200012
|
0.023x |
|
Linedata Services S.A.
PA:LIN
|
0.143x |
|
Global Water Resources Inc
NASDAQ:GWRS
|
0.097x |
|
AMIA Co. Ltd.
TW:8438
|
0.062x |
|
Vendome Acquisition Corporation I Class A Ordinary Shares
NASDAQ:VNME
|
-0.289x |
|
Eightco Holdings Inc.
NASDAQ:ORBS
|
-0.005x |
Annual Cash Flow Conversion Efficiency for TriSalus Life Sciences Inc. (2021–2024)
The table below shows the annual cash flow conversion efficiency of TriSalus Life Sciences Inc. from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see TriSalus Life Sciences Inc. market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-25.89 Million | $-40.84 Million | 1.577x | -15.60% |
| 2023-12-31 | $-27.07 Million | $-50.58 Million | 1.869x | -28.73% |
| 2022-12-31 | $-12.32 Million | $-32.31 Million | 2.622x | +456.99% |
| 2021-12-31 | $30.90 Million | $-22.70 Million | -0.734x | -- |
About TriSalus Life Sciences Inc.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemo… Read more